For research use only. Not for therapeutic Use.
MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6[1].
| Catalog Number | R024816 |
| CAS Number | 1007476-63-2 |
| Synonyms | lithium;[1-hexadecoxy-3-(2,2,2-trifluoroethoxy)propan-2-yl] methyl phosphate |
| Molecular Formula | C22H43F3LiO6P |
| Purity | ≥95% |
| InChI | InChI=1S/C22H44F3O6P.Li/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-29-18-21(31-32(26,27)28-2)19-30-20-22(23,24)25;/h21H,3-20H2,1-2H3,(H,26,27);/q;+1/p-1 |
| InChIKey | GDLMLQJISATCEL-UHFFFAOYSA-M |
| SMILES | [Li+].CCCCCCCCCCCCCCCCOCC(COCC(F)(F)F)OP(=O)([O-])OC |
| Reference | [1]. Fisher AB, Dodia C, Chander A, Jain M. A competitive inhibitor of phospholipase A2 decreases surfactant phosphatidylcholine degradation by the rat lung. Biochem J. 1992 Dec 1;288 ( Pt 2)(Pt 2):407-11. |
